Search Results
Your search for ,aGe matches 8736 pages
Showing 1351 - 1400A Pioneering Oncologist, a Pilot, and a Choral Singer, Among Other Things
“There is and always has been, more to me than medicine. Ever since the university, I have loved flying. Ever since school, I have adored choral singing,” writes John F. Smyth, MD, in his memoir Taming the Beast: Memoirs of a Pioneering Cancer Physician. Dr. Smyth is Emeritus Professor of Medical...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK)...
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
BRAF V600E–Mutated Colon Cancer
This is Part 2 of The Evolving Targeted Treatment Landscape for Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. John Strickler, Stacey A. Cohen, and Harshabad Singh discuss the management of BRAF...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
ACCC Releases 2022 Impact Report
The Association of Community Cancer Centers (ACCC)—which represents more than 34,000 multidisciplinary oncology practitioners—outlined successful programs and initiatives in 2022 that advanced oncology care, according to the ACCC's 2022 Impact Report. These new programs and initiatives included...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
Does Discrimination Accelerate Aging in Black Cancer Survivors?
Investigators have found that Black cancer survivors who reported high levels of discrimination showed greater biological aging and frailty than those who reported lower levels of discrimination, according to a new study published by Mandelblatt et al in the journal Cancer. Background...
Low-Dose Tamoxifen to Prevent Recurrence in Patients With Breast Noninvasive Neoplasia: 10-Year Follow-up of TAM-01 Trial
As reported in the Journal of Clinical Oncology by Lazzeroni et al, the 10-year follow-up of the Italian phase III TAM-01 trial has shown that 3 years of low-dose tamoxifen vs placebo continued to be associated with a reduced risk of recurrence of invasive breast cancer or ductal carcinoma in situ...
FDA Approves Dabrafenib/Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma
On March 16, 2023, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar) with trametinib (Mekinist) for pediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both...
COVID-19 Vaccination Rates May Be Lower in Patients With Cancer Who Have Comorbidities, Certain Types of Cancer, and Specific Sociodemographic Factors
Investigators have found that patients undergoing treatment for cancer who have comorbidities, metastatic solid or non–B-cell hematologic malignancies, and those living in areas with lower levels of education and higher levels of unemployment may have lower rates of COVID-19 vaccination, according...
FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants
On March 8, the U.S. Food and Drug Administration (FDA) provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue, or capsule, that forms around breast implants. Previously, on September 8, 2022, the FDA released a safety communication informing the public of reports of...
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
Trends in Active Surveillance for Management of Low-Risk Prostate Cancer in the United States
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Novel Herbal Oncology Program for Management of Cancer Symptoms at an NCI-Designated Cancer Center
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, Guest Editor of the Integrative Oncology series, and Yen ...
PhALLCON Study: Ponatinib Superior to Imatinib in Combination With Chemotherapy in Newly Diagnosed, Ph-Positive ALL
Ponatinib appears to be a more effective tyrosine kinase inhibitor than imatinib in newly diagnosed, Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when combined with reduced-intensity chemotherapy, according to data presented during the ASCO Plenary Series: February 2023...
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight
On March 9, the U.S. Food and Drug Administration (FDA) published updates to the mammography regulations to, among other things, require mammography facilities to notify patients about the density of their breasts, strengthen the FDA’s oversight and enforcement of facilities, and help interpreting...
Highlights of the 2022 Annual Conference of the International Society of Geriatric Oncology
The 2022 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held in Geneva, Switzerland, on October 28–30, 2022. The meeting was held in conjunction with the SIOG 2022 Public Policy Meeting: Global Policy to Action on Cancer in the Aging Population at UN Headquarters...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Radiation Oncology Workforce Expected to Remain Stable Through 2030, According to ASTRO Report
After analyzing the U.S. radiation oncology workforce, investigators projected a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030, according to an American Society for Radiation Oncology (ASTRO) Workforce Taskforce review...
Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant
Researchers have found that screening for residual disease prior to a bone marrow transplant may help physicians identify which adult patients in remission from acute myeloid leukemia (AML) are at risk of relapsing after the procedure, according to a novel study published by Dillon et al in JAMA....
Understanding the Link Between Prognostic Perception and Patient-Oncologist Prognostic Discordance in the Advanced Cancer Setting
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
Study Finds Cancer Screening in the United States Lagged During the Second Year of the COVID-19 Pandemic
In a study reported in the Journal of Clinical Oncology, Star et al found that cancer screening remained below prepandemic levels in the United States during the second year of the COVID-19 pandemic. Study Details Data on past-year receipt of age-eligible screening for breast cancer (women aged 50...
Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment and Overall Survival in Older Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Eng et al found that exposure to antibiotics within 1 year of starting immune checkpoint inhibitor therapy was associated with poorer survival among patients with cancer who were aged 65 years and older. Study Details The population-based...
CheckMate 274: Continued Disease-Free Survival Benefits With Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
With longer-term follow-up, adjuvant nivolumab continued to demonstrate improved disease-free survival, non–urothelial tract recurrence–free survival, and distant metastasis–free survival vs placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after surgery,...
PSA Level at Time of Salvage Radiation Therapy After Radical Prostatectomy and Risk of All-Cause Mortality
In a study reported in the Journal of Clinical Oncology, Derya Tilki, MD, and colleagues identified a prostate-specific antigen (PSA) level cutpoint, above which initiation of salvage radiation therapy after radical prostatectomy was associated with an increased risk of all-cause mortality in...
Studies Focusing on Age- and Race-Related Disparities in Multiple Myeloma and Sickle Cell Disease
Research that addresses the compounding effects of age and race/ethnicity on access to quality health care and patient-centered outcomes such as physical function, frailty, and survival continues to be an emerging area of inquiry in hematology. Accordingly, novel research employing qualitative and...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
Surgeon-Anesthesiologist Familiarity and Short-Term Outcomes in Complex Gastrointestinal Cancer Surgery
In a Canadian population–based retrospective cohort study reported in JAMA Surgery, Hallet et al found that increased familiarity among surgeon-anesthesiologist dyads—measured by annual number of procedures performed together—was associated with better short-term postoperative outcomes in complex...
Vitamin B5 May Help Improve Red Blood Cell Production in Patients With Myelodysplastic Syndromes
Researchers have discovered that vitamin B5 in combination with existing drugs may be the key to improving outcomes in patients with myelodysplastic syndromes (MDS) and ineffective red blood cell production, according to a novel study published by Mian et al in Science Translational Medicine....
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Patients With Cancer
In an analysis reported in JACC: CardioOncology, Zhu et al found that in the United States, Black patients with cancer were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared with White patients, and that White patients were at increased risk of both outcomes...
Prognosis of HER2-Low vs HER2-Negative Breast Cancer
In an analysis of National Cancer Database data reported in JAMA Oncology, Peiffer et al found “minimal prognostic differences” between HER2-low vs HER2-negative breast cancer, with the findings not supporting classification of HER2-low disease as a distinct disease subtype. Study Details The...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Association of Baseline and Subsequent Cardiovascular Health Metrics With Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Van Sloten et al found that better cardiovascular health scores at baseline and improvement in scores over 7 years were associated with a reduced risk of incident cancers. As stated by the investigators, “The commonality...
Prediction Models for Kidney Failure in Long-Term Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Wu et al developed models for predicting kidney failure among 5-year survivors of childhood cancer. Study Details In the study, predictive models were developed using data from 25,483 survivors from the Childhood Cancer Survivor Study (CCSS)...
Prevalence of High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Patients With BRCA1/2 Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Stroot et al identified the prevalence of high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic BRCA1/2 pathogenic variant carriers. Study Details The study included asymptomatic BRCA1/2 pathogenic variant...
Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Carboplatin Adds Benefit, New Study Shows
In a phase III randomized trial conducted in India, the addition of weekly carboplatin to standard taxane/anthracycline–based neoadjuvant chemotherapy improved pathologic complete response rates, event-free survival, and overall survival in patients with triple-negative breast cancer patients aged...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
KarMMa-3: Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Rodriguez‑Otero et al, an interim analysis of the phase III KarMMa-3 trial showed superior progression-free survival with the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) vs...
Neighborhood Social Vulnerability and Its Influence on the Availability of Clinical Trials in Multiple Myeloma
Clinical trials set the treatment standards for cancer care. However, for select populations, such as those who are older, Black, or facing socioeconomic challenges, access to clinical trials and health care generally remains limited. Barriers to clinical trial participation are numerous and...
PRIME II Trial: Breast-Conserving Surgery With or Without Radiotherapy in Early Breast Cancer
As reported in The New England Journal of Medicine by Ian H. Kunkler, MB, BChir, MA, FRCR, and colleagues, the phase III PRIME II trial has shown a higher risk of local recurrence with the omission of adjuvant radiotherapy after breast-conserving surgery in patients aged ≥ 65 years with hormone...
Study Examines Stress and Social Support for LGBTQI Patients With Cancer and Their Caregivers
Investigators have uncovered how current and historical experiences—including discrimination, violence, family rejection, and exclusion—have created a legacy of distress and fear, adversely impacted trust in health-care professionals, and resulted in unmet needs in cancer survivorship and care for...
Pediatric Patients With ALL Living Along the Texas-Mexico Border May Experience Lower Rates of Survival
Investigators have found that pediatric patients with acute lymphoblastic leukemia (ALL) who lived along the Texas-Mexico border were more likely to die within 5 years than those living in other areas of the state, according to a new study published by Castellanos et al in Cancer. Background...
Yale Study Indicates Older Patients Are Excluded From Progress Against Lung Cancer
The widespread use of immune checkpoint inhibitors has led to significant benefits in younger patients with advanced lung cancer; however, older patients have not experienced similar survival benefits, according to research from Yale Cancer Center. The study was published in JAMA Oncology.1 “There ...
Adding Talazoparib to Enzalutamide Extends Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
Intensified Drug Regimen Added to Standard of Care Improves Outcomes in Subset of Patients With High-Risk Prostate Cancer
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
Association of Anthracycline Use With Risk of Congestive Heart Failure Among Patients Treated for Breast Cancer or Lymphoma
In a retrospective, population-based, case-control study reported in JAMA Network Open, Larsen et al found that patients receiving anthracyclines for breast cancer or lymphoma were at a significantly elevated risk of congestive heart failure vs noncancer controls. No significant difference in risk...
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
